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Abstract 
Objective: Sepsis mortality is reported to be high worldwide, however recently the attributable fraction of mortality 
due to sepsis (AFsepsis) has been questioned. If improvements in treatment options are to be evaluated, it is impor‑
tant to know what proportion of deaths are potentially preventable or modifiable after a sepsis episode. The aim 
of the study was to establish the fraction of deaths directly related to the sepsis episode on the general wards and 
emergency departments.
Results: 839 patients were recruited over the two 24‑h periods in 2016 and 2017. 521 patients fulfilled SEPSIS‑3 
criteria. 166 patients (32.4%) with sepsis and 56 patients (17.6%) without sepsis died within 90 days. Out of the 166 
sepsis deaths 12 (7.2%) could have been directly related to sepsis, 28 (16.9%) possibly related and 96 (57.8%) were 
not related to sepsis. Overall AFsepsis was 24.1%. Upon analysis of the 40 deaths likely to be attributable to sepsis, 
we found that 31 patients (77.5%) had the Clinical Frailty Score ≥ 6, 28 (70%) had existing DNA‑CPR order and 17 had 
limitations of care orders (42.5%).
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Introduction
Sepsis is defined as dysregulated host response to infec-
tion, resulting in acute organ dysfunction [1]. In the UK 
sepsis is estimated to be responsible for the deaths of 
44,000 people every year and hospitalizations for this 
condition have more than doubled over the last 10 years 
[2]. Sepsis mortality is reported to be high worldwide, 
however recently the attributable fraction of mortal-
ity due to sepsis (AFsepsis) has been questioned [3]. 
Very recently the Society of Critical Care Medicine and 
the European Society of Intensive Care Medicine expert 
panel on sepsis and septic shock identified this as a key 
research question: what proportion of deaths are poten-
tially preventable or modifiable after a sepsis episode [4]?
Currently, clinicians rely mostly on nonspecific physio-
logical and laboratory abnormalities among patients with 
suspected or definite infection [5, 6]. The lack of reliable 
diagnostic tools makes it more challenging to identify the 
predictors of patient mortality, design randomised con-
trolled trials (RCT) and develop effective treatments for 
this condition [6].
Whilst mortality of patients who have been diagnosed 
with sepsis on the wards or on the ICU is high [7–10], 
there is very little information about whether this high 
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mortality rate could be directly attributed to this diagno-
sis [4].
The primary aim of the study was to establish the frac-
tion of deaths directly related to the sepsis episode on the 
general wards and emergency departments (ED).
Main text
Methods
Secondary analysis of patient episodes was performed 
on patient population recruited into two annual 24-h 
point-prevalence studies on the general wards and ED 
across all Welsh acute hospitals in 2016 and 2017 [7, 8]. 
Each participating hospital was required to have a 24/7 
consultant-level Emergency Department supervision and 
the facility to admit and treat any acutely unwell patient 
in order to be included in the study. On the study days 
we enrolled consecutive patients presenting to the ED or 
being cared for in an acute in-patient ward setting with 
NEWS ≥ 3 and suspected or proven infection. Patients 
were excluded if they were less than 18 years of age or if 
they were already in a Critical Care environment [7, 8].
The methodology of digital data collection and descrip-
tion of the data collector recruitment and performance 
during the study have been described in our previous 
studies [8, 11]. The data were collected from medical and 
nursing records, focusing on patient demographic data, 
baseline co-morbidity and frailty (according to the Dal-
housie Clinical Frailty Scale), clinical observations, labo-
ratory and radiology data to determine sequential organ 
failure assessment (SOFA) and systemic inflammatory 
response syndrome (SIRS) sepsis criteria and involve-
ment of the treating teams (such as critical care input and 
completion of sepsis care bundles) [12]. Patients were fol-
lowed up until 90 days after study enrolment. We did not 
perform a priory sample size calculation, but aimed to 
recruit all eligible patients.
AFsepsis analysis
Deaths attributable to sepsis were evaluated based on 
microbiological, radiological and laboratory evidence. 
Cause of death of non-survivors was stratified into ‘Sepsis 
related’; ‘Possibly sepsis related’ and ‘Non-sepsis related’ 
using the criteria detailed in Table 1. Based on medical or 
nursing evaluation documented in the medical notes, we 
comprehensibly reviewed each decedent’s clinical course 
in the hospital. We included microbiological, radiologi-
cal and laboratory parameters to elucidate if the clinical 
suspicion of infection, which was the study entry crite-
ria in line with the recent SEPSIS-3 definition, could be 
confirmed. Where available, we also reviewed the dis-
charge letters, clinical summaries and death certificates 
to search for any evidence of the death being related to 
sepsis.
Statistical analysis
Categorical variables are described as proportions and 
are compared using Chi square test. Continuous vari-
ables are described as median and inter-quartile range 
and compared using Mann–Whitney U test. A two-tailed 
p-value < 0.05 was considered statistically significant. All 
statistical tests were calculated using SPSS 23.0 (SPSS 
Inc., Chicago, IL).
Table 1 Criteria used for determining sepsis related, possibly sepsis related and non-sepsis related cause of death
CRP C-reactive protein, WCC white cell count
Sepsis related death: all three statements apply
 Within 14 days of sepsis episode
 Significant OR confirmed infectious changes on radiology OR microbiology within 3 days of index episode
 Treated with intravenous antibiotics at the time of index episode
Possibly sepsis related death: at least three out of the six statements apply
 Within 30 days of the sepsis episode while in‑patient
 Significant infection related laboratory results within 3 days of the index episode (CRP/WCC)
 Administration of multiple broad‑spectrum antibiotics (intravenous or oral)
 Clinical symptoms convincing of infective origin (SIRS 3 or more) within 3 days of the index episode
 Unclear/unavailable data on infection on radiology OR microbiology
 Cause of death is “Sepsis”, “Pneumonia” or other infectious origin on death certificate
Non‑sepsis related death: Statements 1 AND 2 PLUS either 3 OR 4 apply
 No infective changes on laboratory AND radiology investigations AND negative microbiology
 Newly discovered OR progression of advanced malignancy (T4 and above) on radiology or pathology
 Death after 30 days of the index episode if points 1 AND 2 apply AND previous limitations on level of care in place at the time of index episode
 Death after hospital discharge following the index episode if points 1 AND 2 apply OR Cause of death is non‑infectious on the death certificate
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Results
In our study we screened 12,477 patients over the two 
24-h study periods in the 14 Welsh hospitals. 839 patients 
had NEWS ≥ 3 and documented clinical suspicion of 
infection and were recruited in the study. Baseline char-
acteristics are summarised in Table 2.
AFsepsis calculations suggest low number of deaths 
directly attributable to sepsis
Out of 839 patients, 222 were non-survivors. 166 patients 
(32.4%) with sepsis (according to SEPSIS-3 criteria) and 
56 patients (17.6%) without sepsis died within 90  days. 
Out of the 166 sepsis deaths 12 (7.2%) could have been 
directly related to sepsis, 28 (16.9%) possibly related and 
96 (57.8%) were not related to sepsis (Fig.  1). Overall 
AFsepsis was 24.1%.
Upon analysis of the 40 deaths likely to be attributable 
to sepsis, we found that 31 patients (77.5%) had the Clini-
cal Frailty Score ≥ 6, 28 (70%) had existing DNA-CPR 
order and 17 had limitations of care orders (42.5%).
AFsepsis is different for different sepsis screening tools
Out of 394 patients with SIRS ≥ 2, 115 died within 90-day 
follow-up. Ten deaths (8.7%) could have been directly 
Table 2 Baseline characteristics of the patients for all recruited patients and comparing the non-survivors with survivors 
within 90-days
Values are number (proportion) or median (range). Comparison between survivors and non-survivors was performed using Chi square or Mann–Whitney U test. 
P-value of less than 0.05 is italic
All patients (n = 839) Non-survivors (n = 222) Survivors (n = 617) P-value
Age, median (range) 73 (18–103) 79.5 (22–103) 70 (18–100) < 0.0001
Sex, male 411 (49%) 120 (54.05%) 291 (47.16%) 0.078
COPD 230 (27.4%) 50 (23.36%) 180 (30.05%) 0.062
Diabetes 173 (20.6%) 64 (29.91%) 109 (18.20%) 0.0003
Drug abuse 13 (1.5%) 0 (0%) 13 (2.17%) 0.03
Heart failure 94 (11.2%) 43 (20.09%) 51 (8.51%) < 0.0001
Hypertension 272 (32.4%) 76 (35.51%) 196 (32.72%) 0.457
Ischaemic heart disease 145 (17.3%) 46 (21.5%) 99 (16.53%) 0.103
Liver disease 24 (2.9%) 11 (5.14%) 13 (2.17%) 0.028
Neuromuscular disease 29 (3.5%) 11 (5.14%) 18 (3.01%) 0.148
Recent chemotherapy 35 (4.2%) 13 (6.07%) 22 (3.67%) 0.137
Smoker 111 (13.2%) 21 (9.81%) 90 (15.03%) 0.057
Ex‑smoker 221 (26.3%) 65 (30.37%) 156 (26.04%) 0.222
Mean number of co‑morbidities, 
median (range)
2 (0–6) 2 (0–6) 1 (0–6) 0.009
Fig. 1 Distribution of patient deaths according to their attribution to sepsis episode
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related to sepsis, 20 (17.4%) possibly related and 72 
(62.6%) were not related to sepsis (Additional file 1: Fig-
ure S1A). Overall AFsepsis was 26.1%.
Investigating AFsepsis for qSOFA we found that 49 
patients with qSOFA ≥ 2 died during the study follow-
up. Six deaths (12.2%) could have been directly related 
to sepsis, 13 (26.5%) possibly related and 21 (42.9%) were 
not related to sepsis (Additional file 1: Figure S1B). Over-
all AFsepsis was 38.8%.
Discussion
To our knowledge this is the first prospective study ana-
lysing the attributable fraction of mortality due to sep-
sis on general wards and ED. We found that the overall 
AFsepsis in patients fulfilling SEPSIS-3 criteria was 
24.1%.
Our analysis shows that burden of sepsis in death 
may be overestimated. This has important implications 
for RCTs, as overestimation of AFsepsis could lead to 
underpowering of the trials and subsequently failure of 
interventional therapies to show statistical difference in 
improvement of patient outcomes [3]. Thus, in agree-
ment with previous studies conducted in the intensive 
care setting we suggest, that AFsepsis should be used in 
designing such trials rather than the overall mortality in 
population of patients suffering from sepsis [3].
The most significant variables in patient survival, both 
in the whole at-risk population and in population of 
patients who died directly due to sepsis, are patient pre-
admission characteristics such as age and patient reserve. 
This is similar to data by Mahalingam et  al. [13] who 
showed that frailty was associated with increased risk of 
developing sepsis as well as increased mortality risk after 
sepsis episode. Strikingly, 28 (70%) of patients who died 
due to sepsis had DNA-CPR order in place meaning their 
death was already anticipated by the treating team inde-
pendently of the current sepsis episode. It is therefore 
possible that more aggressive treatment could bring more 
harm than benefit to this group of patients. On the other 
hand, 12 (30%) of patients whose death was attributable 
to sepsis did not have the DNA-CPR order in place. We 
believe that finding a diagnostic tool to identify this sub-
group of patients is necessary as early, targeted treatment 
in the form of the Sepsis Six bundle could have a substan-
tial long-term benefit in their survival [9]. In our study, 
none of those patients received the complete bundle [7, 
8].
Our results indicate, that revisiting the approach to 
sepsis research is needed [4, 5]. Improvements in sepsis 
diagnostics are necessary, with more accurate screening 
tools able not only to identify patients suffering from sep-
sis but also able to predict patient response to aggressive, 
sepsis specific management. This would enable clinicians 
to decide about pursuing aggressive and invasive thera-
pies as opposed to general supportive care. It is also been 
long recognized that mortality, as an endpoint, presents 
significant challenges in trial design: its interpretation 
depends on the time horizon over which mortality is 
measured; it is a poor tool to use in early phase clinical 
research to improve selection of the study population; 
it also provides no insight regarding clinical efficacy in 
attenuating physiological disturbance [5]. Better diagnos-
tics would improve the understanding of mortality attrib-
utable to sepsis. AFsepsis in turn would inform the design 
of RTCs and provide information used for power calcu-
lations and an optimal patient selection. This change of 
approach to trial design could result in more structured 
development of therapies for patients suffering from sep-
sis and also reduce harm from excessive fluid and oxygen 
administration, antibiotic use and unnecessary testing in 
patients where either systemic infection is not present, or 
it is only a bystander of the ongoing disease process [14].
The strengths of our study include participation of cen-
tres all across Wales including both academic centres and 
general district hospitals using prospective data collec-
tion methods and providing objective reflection of sepsis 
prevalence in NHS hospitals. Our study has high internal 
validity as our previous two studies applied similar meth-
odology [7, 8].
The low proportion of preventable and modifiable ele-
ments of sepsis deaths should inform the design of inter-
ventional studies. More appropriate identification of 
patients who could actually benefit from aggressive sep-
sis specific interventions should be considered not just 
based on acuity, but also on pre-admission trajectories.
Limitations
Our study has some limitations. Firstly, we could have 
missed patients with sepsis who had NEWS below 3 [15, 
16]. However, recent data suggest that the NEWS cut-off 
of 3 may be the most sensitive trigger to screen patients 
for sepsis outside of the intensive care setting [17]. Score 
of 3 is also recommended as an escalation trigger by 
NICE and used in the Sepsis Trust’s Red Flag Sepsis path-
ways. Secondly, our definition of sepsis-related deaths 
is arbitrary. Unfortunately, there is no gold-standard, 
agreed and validated approach to this question and previ-
ous studies have noted that relying on death certificates, 
even when looking at multiple cause of death registries, 
is likely to produce significant underestimation of sepsis 
related deaths [18–20]. These studies agree that prospec-
tive evaluation of causality would be more appropriate 
and our prospective studies using multiple sources of 
information have made this evaluation possible [7, 8, 18–
20]. Further validation of our approach is being carried 
out in separate datasets.
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Thirdly, our dataset was a compromise between cap-
turing all possible determinants of sepsis using different 
screening tools and maintaining simple structure and 
reliability during data collection.
Additional file
Additional file 1: Figure S1. Distribution of patient deaths according to 
their attribution to sepsis episode defined by different sepsis definitions.
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